GSK - GlaxoSmithKline plc
| Previous Close | 40.54 |
| Open | 40.20 |
| Bid | 40.00 x 4000 |
| Ask | 41.41 x 1000 |
| Day's Range | 40.15 - 40.66 |
| 52 Week Range | 35.78 - 42.36 |
| Volume | 2,279,847 |
| Avg. Volume | 3,762,777 |
| Market Cap | 99.346B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 40.88 |
| EPS (TTM) | 0.99 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 2.39 (5.84%) |
| Ex-Dividend Date | 2018-11-15 |
| 1y Target Est | 43.84 |
- The Wall Street Journal•19 hours ago
[$$] U.K. Closes Corruption Probes of GlaxoSmithKline, Rolls-Royce Individuals
Rolls-Royce said it wouldn’t comment beyond noting the news. The SFO launched its probe into GlaxoSmithKline in 2014, looking at the pharmaceutical giant’s operations in a number of countries, including China. Last year, the SFO had requested additional information on the company’s use of third-party advisers.
Reuters•yesterdayBritish fraud office abandons Rolls-Royce, GSK investigations
The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary". The decision, which comes under SFO Director Lisa Osofsky who took the helm last August pledging to review the agency's caseload, weed out weaker cases and propel others forward, underlines the difficulties of prosecuting senior executives. Rolls-Royce paid almost 500 million pounds ($650 million) under a Deferred Prosecution Agreement (DPA) with the SFO in 2017, drawing a line under a four-year investigation into allegations of criminal conduct spanning three decades, at least seven jurisdictions and three of the company's business sectors.
- Zacks•yesterday
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
- Zacks•yesterday
Top Ranked Income Stocks to Buy for February 22nd
Top Ranked Income Stocks to Buy for February 22nd
- Zacks•2 days ago
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
- Zacks•2 days ago
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
- Zacks•2 days ago
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
- Zacks•3 days ago
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
- The Wall Street Journal•4 days ago
[$$] Drug Maker Pernix Therapeutics Files for Bankruptcy, Blaming Competition From Generics
Holdings Inc., which makes painkiller Zohydro and other medications, has filed for bankruptcy protection after drug sales to consumers fell below expectations. It blamed a revenue drop partly on fresh competition with generic versions of its migraine treatment Treximet. In documents filed in U.S. Bankruptcy Court in Wilmington, Del., company officials said they already have a $76 million offer from affiliates of Highbridge Capital Management LLC, which offered to pay cash and forgive some of its debt.
- Zacks•4 days ago
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
- Market Realist•5 days ago
What Analysts Are Recommending for Teva Pharmaceutical This Month
Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower
- Moody's•8 days ago
Innoviva, Inc. -- Moody's announces completion of a periodic review of ratings of Innoviva, Inc.
Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Market Realist•8 days ago
What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
- Zacks•8 days ago
Top Ranked Growth Stocks to Buy for February 15th
Top Ranked Growth Stocks to Buy for February 15th
Market Realist•8 days agoComparing Dividends and Tax Rates for MRK and GSK in 2019
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
- Market Realist•8 days ago
Merck or GlaxoSmithKline: Which Is Controlling Expenses Better?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
- Zacks•9 days ago
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
- Zacks•9 days ago
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up
Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.
- Market Realist•9 days ago
MRK or GSK: Which Is Expected to Report Faster EPS Growth?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
- Market Realist•9 days ago
Is MRK or GSK Expected to Report Faster Revenue Growth in 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
- Market Realist•9 days ago
What Analysts Recommend for Merck and GlaxoSmithKline This Month
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?Share price movements On February 11, Merck & Co. (MRK) closed at $76.71, 1.04% lower than its previous closing price, 45.20% higher than its 52-week low of $52.83, and 4.34% lower
- Zacks•9 days ago
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
- Zacks•9 days ago
Top Ranked Income Stocks to Buy for February 14th
Top Ranked Income Stocks to Buy for February 14th
